The OCEAN study is testing an investigational drug to see how it works in adults with EGPA that has worsened or returned after previous treatment. An investigational drug is one that is not yet approved for use by the general public.
Eosinophilic granulomatosis with polyangiitis (EGPA, formerly Churg-Strauss syndrome) is a condition caused by inflammation as a result of high numbers of certain types of cells in your blood or in your tissues. In most people, EGPA affects the lungs, causing breathing and lung issues, but it can also affect other organs in the body. The exact cause of EGPA is unknown, but an overactive immune system may cause inflammation.
If you qualify, you will be involved with the study approximately 60 weeks (a little over 1 year).
There are rules in place to help protect the rights, safety, and well-being of people who volunteer for research studies. These rules are put in place to make sure studies follow strict scientific and ethical guidelines. Before a clinical research study can begin, a review board must review the study. This group is called an IRB or institutional review board, and is made up of doctors, scientists, and members of the community.
Taking part in this study is totally voluntary and you may stop at any time for any reason. Additionally during the study, you do not have to pay for the study drug or mepolizumab, study supplies, or tests that are part of the OCEAN study.
Before new treatments and medications are made available to the public, they first have to be studied to make sure they’re safe and effective. That’s where research studies come in. A research study, or clinical trial, is a type of medical research that’s used to determine how well a new treatment or medication will work. The goal is simple: To help doctors find safe and effective ways to treat, diagnose or even prevent all kinds of medical conditions.Learn More